Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.32 |
| ▸ | MBTPS1 | Q14703 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765023 | 0.82 | CTSD (0.38) | GHSRSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5099573 | 0.82 | TRPM8 (0.34) | KMT2ATRPM8OPRD1GHSR | |
| SCHEMBL6589694 | 0.81 | SIGMAR1 (0.34) | KMT2ASLC6A2SLC6A4 | |
| SCHEMBL6588189 | 0.79 | — | — | |
| SCHEMBL6590138 | 0.78 | KMT2A (0.38) | KMT2AOPRD1SLC6A2SLC6A4MBTPS1 | |
| SCHEMBL6589085 | 0.77 | HCRTR1 (0.33) | KCNH2 | |
| SCHEMBL5099682 | 0.77 | KMT2A (0.39) | KMT2AOPRD1GHSRSLC6A2SLC6A4 | |
| SCHEMBL6589072 | 0.77 | KMT2A (0.31) | KMT2A | |
| SCHEMBL5971336 | 0.75 | IRAK4 (0.33) | KCNH2 | |
| SCHEMBL6590708 | 0.74 | CHEK1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KMT2A 2920/4885TRPM8 2527/4885OPRD1 3426/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | KMT2A 2410/4885TRPM8 1885/4885OPRD1 3202/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KMT2A 2920/4885TRPM8 2527/4885OPRD1 3426/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KMT2A 2920/4885TRPM8 2527/4885OPRD1 3426/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | KMT2A 2920/4885TRPM8 2527/4885OPRD1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.